Clinical trial
Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator…
NCT00290251 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH · Completed
Key facts
| NCT number | NCT00290251 |
|---|---|
| Title | Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914 |
| Official title | Evaluation of Whether the Selective Progesterone Receptor Modulator CDB-2914 Can Shrink Leiomyomata |
| Lead sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH |
| Collaborators | HRA Pharma Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leiomyoma |
| Intervention type | Drug |
| Interventions | ulipristal acetate 20 mg, ulipristal acetate 10 mg, placebo |
| Enrollment | 72 |
| Start date | Feb 1, 2006 |
| Primary completion | Jul 1, 2009 |
| Completion | Aug 1, 2010 |
| First posted | Feb 10, 2006 |
| Last update posted | Jul 15, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: